XML 259 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity and Stock-Based Compensation
12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement, Noncash Expense [Abstract]  
Stockholders' Equity and Stock-Based Compensation STOCKHOLDERS' EQUITY AND STOCK-BASED COMPENSATION
Stockholders’ Equity
On July 16, 2013, the Company’s Board of Directors approved a repurchase program (the “Repurchase Program”) authorizing the repurchase of up to 20 million shares of the Company’s common stock from time to time on the open market or in privately negotiated transactions. There is no expiration date for the Repurchase Program, and the timing and amount of any shares repurchased under the program will be determined by the Company’s management based on its evaluation of market conditions and other factors. The Repurchase Program may be suspended or discontinued at any time. Any repurchased shares will be available for use in connection with the Company’s equity compensation plans (or any successor plan) and for other corporate purposes. On July 22, 2022, the Company repurchased 3,906 shares of the Company’s common stock for $1 million as part of the Repurchase Program. As of December 31, 2022, approximately 20 million shares remained available for repurchase pursuant to the Repurchase Program. The Company expects to fund any future stock repurchases using the Company’s available cash balances or proceeds from the issuance of debt.
Except as discussed above, neither the Company nor any “affiliated purchaser” repurchased any shares of Company common stock during 2022, 2021 or 2020.
The following table summarizes the Company’s share activity for the years ended December 31 (shares in millions):
202220212020
Preferred stock - shares issued:
Balance, beginning of period3.4 3.4 1.7 
Issuance of MCPS — — 1.7 
Conversion of MCPS to common stock(1.7)— — 
Balance, end of period1.7 3.4 3.4 
Common stock - shares issued:
Balance, beginning of period855.7 851.3 835.5 
Issuance of common stock attributable to stock-based compensation2.6 3.4 4.5 
Conversion of MCPS to common stock11.0 — — 
Common stock issued in connection with acquisitions— 0.1 — 
Common stock issued in connection with LYONs’ conversions— 0.9 0.4 
Other issuance of common stock— — 10.9 
Balance, end of period869.3 855.7 851.3 
On April 15, 2022, all outstanding shares of the Company’s 4.75% MCPS Series A converted to common shares at a rate of 6.6632 common shares per share of preferred stock into an aggregate of 11.0 million shares of the Company’s common stock, pursuant to the terms of the Certificate of Designation governing the Series A Preferred Stock. Danaher issued cash in lieu of fractional shares of common stock in the conversion. The final quarterly cash dividend of $11.875 per share was paid on April 15, 2022.
In May 2020, the Company completed the underwritten public offering of 10.9 million shares of Danaher common stock at a price to the public of $163.00 per share (the “2020 Common Stock Offering”), resulting in net proceeds of approximately $1.7 billion, after deducting expenses and the underwriters’ discount of $54 million. Simultaneously, the Company completed the underwritten public offering of 1.72 million shares of its 5.0% MCPS Series B, without par value and with a liquidation preference of $1,000 per share (the “2020 MCPS Offering”), resulting in net proceeds of approximately $1.7 billion, after deducting expenses and the underwriters’ discount of $49 million. The Company has used the net proceeds from the 2020 Common Stock Offering and the 2020 MCPS Offering for general corporate purposes.
Unless converted earlier in accordance with the terms of the applicable certificate of designations, each share of MCPS Series B will mandatorily convert on April 15, 2023 into a number of shares of the Company’s common stock between the Minimum Conversion Rate of 5.0156 shares and the Maximum Conversion Rate of 6.1441 shares (subject to further anti-dilution
adjustments). The number of shares of the Company’s common stock issuable upon conversion will be determined based on the average volume-weighted average price per share of the Company’s common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately before the Mandatory Conversion Date. Subject to certain exceptions, at any time prior to the Mandatory Conversion Date, holders may elect to convert the MCPS Series B shares into common stock based on the Minimum Conversion Rate (subject to further anti-dilution adjustments). In the event of a fundamental change, the MCPS Series B shares will convert at the fundamental change rates specified in the certificate of designations, and the holders of MCPS Series B shares would be entitled to a fundamental change make-whole dividend.
Holders of MCPS Series B will be entitled to receive, when and if declared by the Company’s Board of Directors, cumulative dividends at the Annual Cumulative Dividend Rate of the Liquidation Preference per share, payable in cash or, subject to certain limitations, by delivery of shares of the Company’s common stock or any combination of cash and shares of the Company’s common stock, at the Company’s election. If declared, dividends on the MCPS Series B shares are payable quarterly on January 15, April 15, July 15 and October 15 of each year (to, and including, the Mandatory Conversion Date), to the holders of record of the MCPS Series B shares as they appear on the Company’s stock register at the close of business on the immediately preceding December 31, March 31, June 30 and September 30, respectively.
Stock-Based Compensation
Stock options, RSUs and PSUs have been issued to directors, officers and other employees under the Company’s 2007 Omnibus Incentive Plan. The 2007 Omnibus Incentive Plan provides for the grant of stock options, stock appreciation rights, RSUs, restricted stock, PSUs or any other stock-based award and cash-based awards. A total of approximately 127 million shares of Danaher common stock have been authorized for issuance under the 2007 Omnibus Incentive Plan. As of December 31, 2022, approximately 45 million shares of the Company’s common stock remain available for issuance under the 2007 Omnibus Incentive Plan.
Stock options granted prior to 2022 under the 2007 Omnibus Incentive Plan generally vest pro rata over a five-year period and terminate ten years from the grant date, though the specific terms of each grant are determined by the Compensation Committee of the Company’s Board (the “Compensation Committee”). Stock options granted subsequent to December 31, 2021 under the amended and restated 2007 Omnibus Incentive Plan generally vest pro rata over a four-year period and terminate ten years from the grant date, though specific terms of each grant are determined by the Compensation Committee. The Company’s executive officers and certain other employees have been awarded options with different vesting criteria, and options granted to outside directors are fully vested as of the grant date. Option exercise prices for options granted by the Company equal the closing price of the Company’s common stock on the New York Stock Exchange on the date of grant.
RSUs issued under the 2007 Omnibus Incentive Plan provide for the issuance of a share of the Company’s common stock at no cost to the holder. RSUs granted prior to 2022 to employees under the 2007 Omnibus Incentive Plan generally provide for pro rata time-based vesting over a five-year period, although executive officers and certain other employees have been awarded RSUs with different vesting criteria. RSUs granted subsequent to December 31, 2021 to employees under the amended and restated 2007 Omnibus Incentive Plan generally vest pro rata over a four-year period, although certain employees have been awarded RSUs with different vesting criteria. The RSUs that have been granted to directors under the 2007 Omnibus Incentive Plan vest on the earlier of the first anniversary of the grant date or the date of, and immediately prior to, the next annual meeting of the Company’s shareholders following the grant date, but the underlying shares are not issued until the earlier of the director’s death or the first day of the seventh month following the director’s retirement from the Board. Prior to vesting, RSUs granted under the 2007 Omnibus Incentive Plan do not have dividend equivalent rights, do not have voting rights and the shares underlying the RSUs are not considered issued and outstanding.
PSUs issued under the 2007 Omnibus Incentive Plan provide for the issuance of a share of the Company’s common stock at no cost to the holder, vest based on specified performance criteria, are subject to an additional holding period following vesting and are entitled to dividend equivalent rights. The PSU dividend equivalent rights are subject to the same vesting and payment restrictions as the related shares, and the shares underlying the PSUs are not considered issued and outstanding.
The equity compensation awards granted by the Company generally vest only if the employee is employed by the Company (or in the case of directors, the director continues to serve on the Company Board) on the vesting date or in other limited circumstances, including following a qualifying retirement. To cover the exercise of options and vesting of RSUs and PSUs, the Company generally issues new shares from its authorized but unissued share pool, although it may instead issue treasury shares in certain circumstances.
The Company accounts for stock-based compensation by measuring the cost of employee services received in exchange for all equity awards granted based on the fair value of the award as of the grant date. The Company recognizes the compensation expense over the requisite service period (which is generally the vesting period but may be shorter than the vesting period if the
employee becomes retirement eligible before the end of the vesting period). The fair value for RSU awards was calculated using the closing price of the Company’s common stock on the date of grant, adjusted for the fact that RSUs do not accrue dividends. The fair value of the PSU awards was calculated using a Monte Carlo pricing model. The fair value of the options granted was calculated using a Black-Scholes Merton option pricing model (“Black-Scholes”).
The following summarizes the assumptions used in the Black-Scholes model to value options granted during the years ended December 31:
 202220212020
Risk-free interest rate
1.8 – 4.0%
0.6 – 1.5%
0.3 – 1.3%
Weighted average volatility30.3 %29.8 %24.3 %
Dividend yield0.4 %0.3 %0.4 %
Expected years until exercise
5.0 – 7.5
5.0 – 7.5
5.0 – 8.0
The Black-Scholes model incorporates assumptions to value stock-based awards. The risk-free rate of interest for periods within the contractual life of the option is based on a zero-coupon U.S. government instrument whose maturity period equals or approximates the option’s expected term. Expected volatility is based on implied volatility from traded options on the Company’s stock and historical volatility of the Company’s stock. The dividend yield is calculated by dividing the Company’s annual common stock dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. To estimate the option exercise timing used in the valuation model (which impacts the risk-free interest rate and the expected years until exercise), in addition to considering the vesting period and contractual term of the option, the Company analyzes and considers actual historical exercise experience for previously granted options. The Company stratifies its employee population into multiple groups for option valuation and attribution purposes based upon distinctive patterns of forfeiture rates and option holding periods, as indicated by the ranges set forth in the table above for the risk-free interest rate and the expected years until exercise.
The amount of stock-based compensation expense recognized during a period is also based on the portion of the awards that are ultimately expected to vest. The Company estimates pre-vesting forfeitures at the time of grant by analyzing historical data and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. Ultimately, the total expense recognized over the vesting period will equal the fair value of awards that actually vest.
The following summarizes the components of the Company’s continuing operations stock-based compensation expense for the years ended December 31 ($ in millions):
 202220212020
RSUs/PSUs:
Pretax compensation expense$195 $129 $114 
Income tax benefit(40)(26)(24)
RSU/PSU expense, net of income taxes155 103 90 
Stock options:
Pretax compensation expense141 89 73 
Income tax benefit(28)(18)(15)
Stock option expense, net of income taxes113 71 58 
Total stock-based compensation:
Pretax compensation expense336 218 187 
Income tax benefit(68)(44)(39)
Total stock-based compensation expense, net of income taxes$268 $174 $148 
Stock-based compensation has been recognized as a component of selling, general and administrative expenses in the accompanying Consolidated Statements of Earnings. As of December 31, 2022, $204 million of total unrecognized compensation cost related to RSUs/PSUs is expected to be recognized over a weighted average period of approximately two years. As of December 31, 2022, $240 million of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted average period of approximately two years. Future compensation amounts will be adjusted for any changes in estimated forfeitures.
The following summarizes option activity under the Company’s stock plans (in millions, except weighted exercise price and number of years):
OptionsWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (in years)Aggregate Intrinsic Value
Outstanding as of January 1, 202017.0 $82.95 
Granted 2.9 160.71 
Exercised (3.5)62.54 
Cancelled/forfeited (0.5)113.94 
Outstanding as of December 31, 202015.9 100.65 
Granted2.8 240.75 
Exercised(2.4)79.16 
Cancelled/forfeited(0.7)144.60 
Outstanding as of December 31, 202115.6 127.13 
Granted2.3 269.10 
Exercised(1.6)89.62 
Cancelled/forfeited(0.6)198.85 
Outstanding as of December 31, 202215.7 149.01 6$1,847 
Vested and expected to vest as of December 31, 2022 (a)
15.3 $147.34 6$1,833 
Vested as of December 31, 20228.2 $102.64 5$1,341 
(a)    The “expected to vest” options are the net unvested options that remain after applying the forfeiture rate assumption to total unvested options.
The aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between the Company’s closing stock price on the last trading day of 2022 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2022. The amount of aggregate intrinsic value will change based on the price of the Company’s common stock.
The weighted average per share grant-date fair values of options granted during 2022, 2021 and 2020 were $80.32, $64.57 and $37.42, respectively.
Options outstanding as of December 31, 2022 are summarized below (in millions, except price per share and number of years):
 OutstandingExercisable
Exercise PriceSharesAverage Exercise PriceAverage Remaining Life (in years)SharesAverage Exercise Price
$39.6 to $66.79
1.8 $62.75 21.8 $62.75 
$66.8 to $92.41
2.4 81.60 42.4 81.60 
$92.42 to $141.10
4.4 107.41 52.7 105.90 
$141.11 to $249.18
4.2 185.12 71.1 173.94 
$249.19 to $299.68
2.9 272.79 90.2 283.43 
The aggregate intrinsic value of options exercised during the years ended December 31, 2022, 2021 and 2020 was $288 million, $446 million and $415 million, respectively. Exercise of options during the years ended December 31, 2022, 2021 and 2020 resulted in cash receipts of $130 million, $167 million and $211 million, respectively. Upon exercise of the award by the employee, the Company derives a tax deduction measured by the excess of the market value over the grant price at the date of exercise. The Company realized a tax benefit of $48 million, $83 million and $82 million in 2022, 2021 and 2020, respectively, related to the exercise of employee stock options.
The following summarizes information on unvested RSU and PSU activity (in millions, except weighted average grant-date fair value):
Number of RSUs/PSUsWeighted Average
Grant-Date Fair Value
Unvested as of January 1, 20203.5 $94.85 
Granted1.1 159.93 
Vested(1.0)91.08 
Forfeited(0.2)111.59 
Unvested as of December 31, 20203.4 116.03 
Granted0.9 234.52 
Vested(1.0)101.86 
Forfeited(0.2)147.20 
Unvested as of December 31, 20213.1 152.99 
Granted1.1 268.00 
Vested(1.0)159.42 
Forfeited(0.2)202.55 
Unvested as of December 31, 20223.0 189.71 
The Company realized a tax benefit of $37 million, $35 million and $18 million in the years ended December 31, 2022, 2021 and 2020, respectively, related to the vesting of RSUs and PSUs.
The excess tax benefit of $61 million, $95 million and $85 million related to the exercise of employee stock options and vesting of RSUs and PSUs for the years ended December 31, 2022, 2021 and 2020, respectively, has been recorded as a reduction to the current income tax provision and is reflected as an operating cash inflow in the accompanying Consolidated Statements of Cash Flows.
In connection with the exercise of certain stock options and the vesting of RSUs previously issued by the Company, a number of shares sufficient to fund statutory minimum tax withholding requirements has been withheld from the total shares issued or released to the award holder (though under the terms of the applicable plan, the shares are considered to have been issued and are not added back to the pool of shares available for grant). During the year ended December 31, 2022, 362 thousand shares with an aggregate value of $99 million were withheld to satisfy the requirement. During the year ended December 31, 2021, 346 thousand shares with an aggregate value of $81 million were withheld to satisfy the requirement. The withholding is treated as a reduction in additional paid-in capital in the accompanying Consolidated Statements of Stockholders’ Equity and a reduction in proceeds from the issuance of common stock in connection with stock-based compensation in the Consolidated Statements of Cash Flows.
Accumulated Other Comprehensive Income
The changes in accumulated other comprehensive income (loss) by component are summarized below ($ in millions).
Foreign Currency Translation AdjustmentsPension and Postretirement Plan Benefit AdjustmentsCash Flow Hedge AdjustmentsAccumulated Comprehensive Income (Loss)
Balance, January 1, 2020$(2,174)$(781)$(113)$(3,068)
Other comprehensive income (loss) before reclassifications:
Increase (decrease)2,894 (239)(432)2,223 
Income tax impact25 57 — 82 
Other comprehensive income (loss) before reclassifications, net of income taxes2,919 (182)(432)2,305 
Reclassification adjustments
Increase (decrease)— 46 
(a)
361 
(b)
407 
Income tax impact— (11)(1)(12)
Reclassification adjustments, net of income taxes— 35 360 395 
Net other comprehensive income (loss), net of income taxes2,919 (147)(72)2,700 
Balance, December 31, 2020745 (928)(185)(368)
Other comprehensive income (loss) before reclassifications:
Increase (decrease)(1,277)436 523 (318)
Income tax impact(7)(102)(104)
Other comprehensive income (loss) before reclassifications, net of income taxes(1,284)334 528 (422)
Reclassification adjustments
Increase (decrease)— 58 
(a)
(280)
(b)
(222)
Income tax impact— (14)(1)(15)
Reclassification adjustments, net of income taxes— 44 (281)(237)
Net other comprehensive income (loss), net of income taxes(1,284)378 247 (659)
Balance, December 31, 2021(539)(550)62 (1,027)
Other comprehensive income (loss) before reclassifications:
Increase (decrease)(2,051)233 378 (1,440)
Income tax impact(54)(56)(91)(201)
Other comprehensive income (loss) before reclassifications, net of income taxes(2,105)177 287 (1,641)
Reclassification adjustments
Increase (decrease)— 42 
(a)
(235)
(b)
(193)
Income tax impact— (10)(1)(11)
Reclassification adjustments, net of income taxes— 32 (236)(204)
Net other comprehensive income (loss), net of income taxes(2,105)209 51 (1,845)
Balance, December 31, 2022$(2,644)$(341)$113 $(2,872)
(a)    This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension and postretirement cost (refer to Note 16 for additional details).
(b)    Reflects reclassification to earnings related to remeasurement of certain long-term debt (refer to Note 15 for additional details).